Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Old drug, new hope? pentoxifylline trial targets jaundice

NCT ID NCT06944704

Disease control Sponsor: Tanta University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jul 22, 2026 · Updated 2 times

Summary

This completed Phase 2 trial tested whether the drug pentoxifylline can help people with jaundice caused by liver or bile duct problems. 45 adults took 400 mg of pentoxifylline twice daily for 3 months, alongside standard care. Researchers measured changes in antioxidant levels, inflammation, and liver function to see if the drug improves bilirubin and liver health.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Pentoxifylline
What this could lead to
If it works, this could point toward a new way to reduce jaundice and improve liver function in people with liver or bile duct problems.
What could go wrong
This is a small, early-phase trial with only 45 people, so results may not apply to everyone. Pentoxifylline can cause side effects like nausea or bleeding risk.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

45 people

The number who actually took part.

Started

Apr 2024

Finished

Mar 2025

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 70 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Patients age 18-70 years old. * Patients diagnosed with jaundice and increased level direct bilirubin ≥ 3 mg/dL. Exclusion Criteria: * Pregnancy. * Nursing mothers. * Patients with increased indirect bilirubin level. * Patients who have Gilbert syndrome or Crigler Najjar syndrome. * History of intolerance and hypersensitivity to Pentoxifylline or to xanthine derivatives such as caffeine, theophylline. * Recent hemorrhage. * Patients who have risk factors potentially complicated by hemorrhage. * Taking anticoagulants or antiplatelet therapy.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Hepatobiliary disorders are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Digestive System Diseases hepatobiliary disorder Jaundice obstructive jaundice

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Hepatobiliary disorders

Contacts and locations

Locations

  • Faculty of Pharmacy, Tanta University

    Tanta, 31111, Egypt

More trials for these conditions

Other studies related to the condition(s) this trial covers.